The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti‐CD38
monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy …

Competent T-cells with sufficient levels of fitness combat cancer formation and progression.
In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor …

Objective Ischemic stroke has become one of the leading diseases for international death,
which brings burden to the economy and society. Exosomes (Exos) derived following neural …

塞利尼索是全球首个强效, 口服的核输出蛋白抑制剂, 具备独特的作用机制且影响多条信号通路,
能协同增强其他药物的抗肿瘤活性. 国内外多项临床研究证实以塞利尼索为基础的联合方案治疗 …

We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd)
in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to …

Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that
inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple …

The therapeutic options available for patients with multiple myeloma have greatly expanded
over the past decade and incorporating these novel agents into routine clinical practice has …

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma,
particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor …

Background Dose modifications in response to adverse events (AEs) can maintain tumor
response and improve therapy tolerability. We conducted a post-hoc analysis of the efficacy …